Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | SC |
no titers after administration/zero immunity; This non-serious case was reported by a consumer via call center representative and described the occurrence of therapy non-responder in a female patient who received MMR (Priorix) for prophylaxis. In APR-2025, the patient received Priorix (subcutaneous use). On an unknown date, an unknown time after receiving Priorix, the patient experienced therapy non-responder (Verbatim: no titers after administration/zero immunity). The outcome of the therapy non-responder was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 20-JUN-2025 The patient called to request information about Priorix and the development of titers after vaccination. The patient received a dose of the GlaxoSmithKline MMR vaccine (did not confirm it was Priorix but it was from GlaxoSmithKline), and after receiving the dose in late April 2025, no titers were developed (reported: zero immunity). The patient was unsure if any previous doses had been administered. A pharmacist recommended receiving another dose, checking titers again, and, if there was still no response, consulting with an immunologist. The vaccine administration facility was the same as the primary reporter.